Mirum Pharmaceuticals, Inc. (MIRM) Stock Price & Analysis

Mirum Pharmaceuticals, Inc. (MIRM) rose 2.02% to USD 95.48 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.

MIRM last closed at USD 93.59; the session ranged USD 91.97–96.59 on volume of 683,241 shares. Market capitalization is $5.82B, with a 52-week range of USD 47.15–114.99 (NGM). Source: Nexqual, June 10, 2026 at 00:44 UTC.

Key Statistics (as of June 10, 2026 at 00:44 UTC)

Technical Analysis (MIRM)

Nexqual's technical model rates MIRM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.

Analyst Ratings (MIRM)

Wall Street analysts rate MIRM "Strong Buy" based on 14 analysts, with a mean price target of USD 144.21 (range USD 115–185), per Nexqual as of June 10, 2026 at 00:44 UTC.

Earnings (MIRM)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financials & Fundamentals (MIRM)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financial Health Score (MIRM)

Nexqual rates Mirum Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:44 UTC.

Ownership (MIRM)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Leadership (MIRM)

Mirum Pharmaceuticals, Inc. is led by Christopher Peetz (age 46), CEO & Director, per Nexqual as of June 10, 2026 at 00:44 UTC.

Major Backers & Investors (MIRM)

Notable institutional backers of Mirum Pharmaceuticals, Inc. include Frazier Life Sciences Management, L.P. , Janus Henderson Group PLC, FMR, LLC, according to Nexqual as of June 10, 2026 at 00:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

From Mirum Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Food and Drug Administration ("FDA") approved Cholbam in March 2015 as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder ("PBD-ZSD").
• We submitted a New Drug Application ("NDA") for chenodiol for the treatment of CTX in 2024 and received FDA approval for the treatment of adults with CTX in February 2025.
• Cholbam for the treatment of bile acid synthesis disorders and peroxisomal disorders, including PBD-ZSD The FDA approved Cholbam (cholic acid capsules) in March 2015, as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including PBD-ZSD.
• Our success also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights.

Partnerships

• License, Finance, Royalty Agreements and Asset Purchases Assignment and License Agreement with Shire International GmbH (Takeda) In November 2018, we entered into an assignment and license agreement ("Shire License Agreement") with Shire International GmbH ("Shire"), which was subsequently acquired by Takeda Pharmaceutical Company Limited.
• License Agreement with Sanofi-Aventis Deutschland GmbH Through the Shire License Agreement, we were assigned the rights to the license agreement, as amended ("Sanofi Agreement"), with Sanofi-Aventis Deutschland GmbH ("Sanofi"), under which we obtained an exclusive, worldwide license to certain patents and know-how controlled by Sanofi related to volixibat ("Sanofi Technology").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.